3BBLACKBIO
Composite scorecard: 72/100 — Quality 100 · Valuation 33
| Share price | ₹1,267.40 |
| P/B ratio | 3.0 |
| ROE | 19.9% |
| Book value | ₹388.37 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹142 Cr | ₹60 Cr | 40.0% |
| 2025 | ₹96 Cr | ₹48 Cr | 52.0% |
| 2024 | ₹74 Cr | ₹32 Cr | 44.0% |
| 2023 | ₹62 Cr | ₹26 Cr | 47.0% |
| 2022 | ₹81 Cr | ₹32 Cr | 46.0% |
3B Blackbio Dx Limited engages in the design, development, manufacturing, and commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance in India. The company offers qPCR-based and lateral flow assays rapid tests and Next Gen Sequencing -based molecular diagnostic kits for accurate and reliable testing on patient samples under the TRUPCR, TRUNGS, TRURAPID, brand for testing on patient samples to diagnostics labs. It also offers agrochemical products; technical support and training services. 3B Blackbio Dx Limited was incor